An anti-vegf-b antibody reduces abnormal tumor vasculature and enhances the effects of chemotherapy

HIGHLIGHTS

• What: The authors investigated the VEGFR1 ligand which the authors demonstrate to be expressed in cells and in stroma and vasculature across a range of types. All animal experiments described in this study were approved by the animal ethics committee of the Austin Hospital (approval 2009/03381) and were conducted in compliance with the NHMRC guidelines "Australian code of practice for the care and use of animals for scientific purposes".
• Who: Peter W. Janes et al. from the Tumour Targeting Program, Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, Australia School of Cancer Medicine, La . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.